Research Study

A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
Principal Investigator 
Sasha Smiljanic

Overview

Body Locations and Systems 
Breast Cancer
Disorders and Conditions 
Breast Cancer
Health Conditions 
Breast Cancer
ClinicalTrials.gov# 
NCT01966471
Status 
Closed to Recruitment
Study Start/End 
Feb 17, 2014 to Jun 3, 2024
Locations 
Lions Gate Hospital
Name/Title 
Valla Sahraei, Research Coordinator
Phone 
604-988-3131 ext.4934
Email Address 
valla.sahraei@vch.ca
Purpose of Study 

This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of Kadcyla (trastuzumab emtansine, also known as T-DM1) in combination with Perjeta (pertuzumab) versus Herceptin (trastuzumab) in combination with Perjeta and a taxane as adjuvant therapy in patients with HER2-positive primary invasive breast cancer. Following surgery and anthracycline-based chemotherapy, patients will receive either Kadcyla 3.6 mg/kg and Perjeta 420 mg intravenously (iv) every three weeks or Herceptin 6 mg/kg iv every three weeks in combination with Perjeta and a taxane. Anticipated time on HER2 targeted study treatment is up to 1 year.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.